<?xml version="1.0" encoding="UTF-8"?>
<p>The use of AI is prevalent in drug discovery, and many pharmaceutical corporations have established in-house partnerships or initiatives with AI companies. Some organizations are currently using AI approaches to find novel uses for late-stage drug candidates or repurpose existing drugs [
 <xref rid="ref34" ref-type="bibr">34</xref>,
 <xref rid="ref35" ref-type="bibr">35</xref>]. However, data of sufficient quality are needed to train systems for COVID-19 AI implementation. Data accessibility is an additional challenge because the systems will be trained via supervised learning, which requires substantial amounts of data on COVID-19 to accurately perform complex tasks.
</p>
